Ally Financial: Street Splits After Q3 Print

Ally Financial just printed Q3 results and the immediate reaction from analysts is a study in disagreement, with one firm downgrading, several trimming targets, and JP Morgan moving the other way.

The analyst response to the earnings release tells the sharpest story. Evercore ISI cut ALLY to In-Line from Outperform this morning, lowering its target to $40 from $44. That is a meaningful shift from a firm that had been constructive. Barclays and TD Cowen both trimmed targets while holding their ratings, with Barclays cutting from $56 to $48 and TD Cowen from $54 to $52. JP Morgan moved against the grain, lifting its target by a dollar to $44 while maintaining Overweight. The net result is a consensus that remains nominally bullish (nine buys, five holds, mean target at $47.62) but is clearly recalibrating. Morgan Stanley had already moved to Equal-Weight from Overweight on October 12, so the direction of travel this month has been firmly downward for most of the Street. With the stock at $37.97, the mean target implies roughly 25% upside, though the rapid pace of target cuts over the past two weeks signals that number may not hold.

The bull case rests on the consumer auto portfolio, which held relatively stable at $83.9 billion, and on the expectation that margins improve from here as funding costs ease. Bears point to the sequential decline in net financing revenues and the continued contraction in commercial auto loans. The valuation picture is not demanding: ALLY trades at roughly 6.4 times earnings and 0.76 times book, both of which have drifted lower over the past month. EPS momentum factor scores are weak (12th percentile on the 30-day measure), but the earnings surprise rank is a more neutral 59th percentile.

Short positioning has nudged lower on the week and is essentially flat over five days at just over 5% of the free float. That 5% level remains modestly elevated versus where it was in mid-September (around 13.9 million shares versus 13.9 million then, with the bulk of the month's 11% increase having come in a step-change around October 8). What is notable post-earnings is the shift in borrow dynamics: availability has surged to 8,931%, up 63% on the week, meaning the lending pool is now exceptionally loose by recent standards. Borrowing costs are a trivial 0.46%. This is not a short that is being squeezed, and the easy availability suggests bears face no friction in maintaining or adding to positions if the fundamental case deteriorates further. Options positioning is broadly neutral, with the put/call ratio at 0.87, barely above its 20-day average of 0.86 and only a third of a standard deviation from the mean.

One data point worth carrying alongside the analyst debate comes from the FDIC call reports tracked by ORTEX Alt Data. Ally's insured bank charter reported its largest Q2 for total deposits on record (since 2024), with deposits hitting $156.6 billion, and total assets have risen for four consecutive quarters to $188.2 billion. Neither FDIC series has accumulated enough history to test whether it leads the company's reported figures, so these readings are colour rather than signal. But they do paint a balance sheet that, at least through June, was growing rather than contracting.

Insider activity over the past 90 days is dominated by transaction-code "A" awards to directors (routine compensation grants), with the one discretionary open-market transaction being the CRO's $221,000 sale in August under a pre-arranged 10b5-1 plan. There is no meaningful signal from insiders here.

The next scheduled earnings event is in January 2027. Between now and then, the question is whether the analyst community stabilises around current, lower targets or continues to ratchet them down as the credit cycle picture becomes clearer.